echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Zhifei Biology/Institute of Microbiology, Chinese Academy of Sciences Recombinant New Coronary Vaccine Obtained Emergency Use Approval

    Zhifei Biology/Institute of Microbiology, Chinese Academy of Sciences Recombinant New Coronary Vaccine Obtained Emergency Use Approval

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 10, the recombinant new coronavirus vaccine (CHO cell) jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Zhifei Biotechnology was approved for emergency use in China, becoming the fourth domestic new coronavirus vaccine approved for emergency use.


    It is reported that the vaccine has completed Phase I and Phase II clinical trials in October last year.


    In November last year, the vaccine successively launched phase III clinical trials in China, Uzbekistan, Pakistan, Ecuador, and Indonesia, with 29,000 patients planned to be vaccinated.


    It is reported that the vaccine production uses engineered cells (CHO) to produce recombinant proteins, and does not require high-grade biosafety laboratory production workshops.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.